News

Cocrystal Pharma (COCP) – 3Q26 Announced With Phase 1b Trial Data Expected Shortly

Health
0 min read


Tuesday, November 17, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

3Q26 Reported With CDI-988 Data Expected. Cocrystal announced a 3Q26 loss of $3.4 million, or $(0.20) per share. The Phase 1b human challenge study testing CDI-988 in norovirus completed dosing of its last patient in September 2026. Preliminary data are expected later in FY2026. The company had $4.9 million in cash on September 30, 2026.

CDI-988 Completed Patient Enrollment In September 2026. CDI-988 is currently in a Phase 1b human challenge study for prevention and treatment of norovirus. The study enrolled 32 healthy adults, aged 18 to 49, in stages. Volunteers in the prevention and treatment arms were inoculated with the norovirus GII.2 (Snow Mountain Virus) strain, followed by either CDI-988 (1,200 mg twice daily for five days) or placebo. The last subject was dosed in September 2026, with preliminary efficacy results expected in late 2026.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Share

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy